Overall and subgroup prevalence of pyoderma gangrenosum among patients with hidradenitis suppurativa: A population-based analysis in the United States - 16/05/19
Abstract |
Background |
Hidradenitis suppurativa (HS) and pyoderma gangrenosum (PG) are reported to coexist, although the prevalence of PG among patients with HS has not been systematically evaluated.
Objective |
To evaluate PG prevalence among patients with HS.
Methods |
Cross-sectional analysis of adults with PG among patients with HS and patients without HS through use of electronic health records data from a population-based sample of 55 million patients.
Results |
The prevalence of PG among 68,232 patients with HS was 0.18% (125 of 68,232), compared with 0.01% (1835 of 31,435,166) among those without HS (P < .0001). Prevalence was markedly higher among patients with HS and Crohn's disease (CD) (3.68%) than among patients with HS but without CD (0.12%). The odds of having PG were 21.14 (95% confidence interval [CI], 17.51-25.51) times greater among patients with HS than among those without HS. Patients with HS with CD had 12.38 (95% CI, 9.15-16.74) times the odds of having PG than did patients without HS but with CD. Among patients without CD, compared with patients without HS, those with HS had 26.51 (95% CI, 21.07-33.36) times the odds of having PG.
Limitations |
We could not establish HS phenotype among those having coexistent PG, nor could we distinguish syndromic from nonsyndromic cases.
Conclusion |
Patients with HS have an increased prevalence of PG, regardless of CD status. Painful ulcerations among patients with HS warrant additional evaluation for PG.
Le texte complet de cet article est disponible en PDF.Key words : acne, ankylosing spondylitis, conglobata, Crohn's disease, Explorys, hidradenitis suppurativa, PADH, PAPASH, PASS, pyoderma gangrenosum, pyogenic arthritis
Abbreviations used : CI, HS, ICD, ICD-9, PAPASH, PASH, PASS, PG, SNOMED-CT
Plan
Funding sources: Supported in part by an education grant from AbbVie. The sponsor had no role in the design and conduct of the study; collection, management, analysis and interpretation of data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. |
|
Disclosure: Dr Garg has served as an advisor for AbbVie, Pfizer, Janssen, Asana Biosciences, and UCB and has received honoraria. Ms Tannenbaum and Mr Strunk have no conflicts of interest to disclose. |
|
Reprints not available from the authors. |
Vol 80 - N° 6
P. 1533-1537 - juin 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?